Correction: Normal Lung Quantification in Usual Interstitial Pneumonia Pattern: The Impact of Threshold-based Volumetric CT Analysis for the Staging of Idiopathic Pulmonary Fibrosis.

[This corrects the article DOI: 10.1371/journal.pone.0152505.].

The ninth author’s name is spelled incorrectly. The correct name is: Nobukata Kazawa.

In Table 3 the description of the dose of pirfenidone is incorrect. The correct dose of pirfenidone is: 600 mg (n)/1200mg(n)/1800mg(n). Please see the corrected Table 3 here.

Table 3

Clinical and physiologic data of the study population.

Parameters	IPF patients	Control
Total (n)	27	13
Gender, male/female (n)	17 / 10	3 / 10
Age (years)	75.5 ± 6.9	59.5 ± 11.8
Never smoker (n)	10	8
Past smoker (n)	17	5
(pack-year)	51 ± 34	23 ± 14.4
Body mass index (kg/m2)	22.4 ± 3.7	23.9 ± 3.1
Japanese stage I (n) / II (n) / III (n) / IV (n)	11 / 4 / 9 / 3	NA
GAP stage I (n) / II (n) / III (n)	12 / 6 / 9	NA
Serum KL-6 (U/mL)	1256 ± 1057	NA
Treatment with prednisolone (n)	8	NA
Dose of prednisolone (mg)	11.5 ± 4.9*	NA
Treatment with pirfenidone (n)	12	NA
Dose of pirfenidone, 600 mg (n)/1200mg (n)/1800mg (n)	5 / 4 / 3	NA
Home oxygen treatment (n)	7	NA
sPAP assessed with echocardiography >45 Torr (n)	3	NA
FVC (mL)	2303 ± 770	3080 ± 835
%FVC (%)	79.2 ± 18.3	112 ± 20.6
FEV1/FVC (%)	84.1 ± 9.9	76.3 ± 8.5
DLco (mL/min/mmHg)	9.1 ± 3.8	NA
%DLco (%)	42.8 ± 16.4	NA
TLC (mL)	3568 ± 1001	NA